More drugs originate outside the industry than it claims
Abstract
Many innovative drugs, especially to treat rare diseases, originate not from large drug companies but from small enterprises or academia, a new study has shown. The research by the European Medicines Agency shows that 44% of innovative drugs recommended for marketing authorisation in the European Union originated from small or medium sized enterprises, academia, public bodies, and public-private partnerships.1 This seems to contradict the claim by Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, that the industry was responsible for developing 90% of the drugs available to patients. …
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Almost half of the remaining research and development figure is paid for by public funds, bringing the estimate down to $90 million to $300 million.
“Furthermore, almost half of the remaining figure for R&D is actually paid for by public funds (such as universities, the WHO, the Gates Foundation, and NIH), bringing the estimate down to $90 to $300 million [32,34].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [34]
Cited by
Sorted by citations
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69 · see citing works
“Furthermore, almost half of the remaining figure for R&D is actually paid for by public funds (such as universities, the WHO, the Gates Foundation, and NIH), bringing the estimate down to $90 to $300 million [32, 34].”
Background
- Authors
- Young, J.
- Corresponding author
- Young, J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-02-04
- Volume
- 348
- Issue
- feb04 14
- Pages
- g1354-g1354
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W1990526030
- Cited by
- 1
- References
- 0
- Citations by year
- 2023: 1
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Biotechnology and Related Fields
- Keywords
- small and medium-sized enterprises, academia, public-private partnerships, rare diseases, pharmaceutical industry, drug approval, European Medicines Agency, Association of the British Pharmaceutical Industry
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Orphan Drug Production, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
